DekaBank Deutsche Girozentrale Increases Holdings in Avantor, Inc. (NYSE:AVTR)

DekaBank Deutsche Girozentrale boosted its position in Avantor, Inc. (NYSE:AVTR) by 146.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 400,736 shares of the company’s stock after buying an additional 238,285 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Avantor were worth $10,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Fifth Third Bancorp lifted its holdings in shares of Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after buying an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its position in Avantor by 565.5% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after purchasing an additional 1,131 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Avantor during the 4th quarter worth approximately $42,000. Montag A & Associates Inc. purchased a new position in shares of Avantor during the 4th quarter valued at approximately $43,000. Finally, TFO Wealth Partners LLC lifted its stake in shares of Avantor by 203,100.0% in the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after purchasing an additional 2,031 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Buying and Selling

In other Avantor news, insider Christophe Couturier 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVTR. Barclays raised their price target on shares of Avantor from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Robert W. Baird upped their price target on Avantor from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $30.00 to $23.00 in a report on Wednesday, July 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of Avantor in a research note on Monday, July 29th. Finally, Morgan Stanley lifted their price target on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.21.

Avantor Stock Performance

NYSE AVTR traded down $0.90 on Friday, hitting $25.60. 11,282,011 shares of the company’s stock were exchanged, compared to its average volume of 15,055,082. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The firm’s 50-day moving average price is $22.59 and its two-hundred day moving average price is $23.79. The firm has a market cap of $17.40 billion, a price-to-earnings ratio of 65.64, a P/E/G ratio of 2.71 and a beta of 1.32. Avantor, Inc. has a fifty-two week low of $16.63 and a fifty-two week high of $28.00.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.